Literature DB >> 22290629

Pediatric intensive care unit: an essential service to improve survival of childhood cancer in developing world.

Ramzan Ramzan, Satya P Ramzan, Dhiren Gupta, Sanjeev Arora, Anupam Sanjeev.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22290629     DOI： 10.1007/s12098-012-0686-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  5 in total

1.  Improved outcomes of children with malignancy admitted to a pediatric intensive care unit.

Authors:  A R Hallahan; P J Shaw; G Rowell; A O'Connell; D Schell; J Gillis
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

2.  Survival outcome in childhood acute lymphoblastic leukemia in India.

Authors:  Satya Prakash Yadav; Manas Kalra; Madasu Anjan; Anupam Sachdeva
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

3.  Sepsis is a major barrier to improving survival in childhood acute lymphoblastic leukemia in the developing world.

Authors:  Satya Prakash Yadav; Vikas Dua; Anupam Sachdeva
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

Review 4.  International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.

Authors:  Brahm Goldstein; Brett Giroir; Adrienne Randolph
Journal:  Pediatr Crit Care Med       Date:  2005-01       Impact factor: 3.624

5.  Outcome and prognostic factors seen in pediatric oncology patients admitted in PICU of a developing country.

Authors:  Nida Akhtar; Zehra Fadoo; Sukaina Panju; Anwarul Haque
Journal:  Indian J Pediatr       Date:  2011-03-25       Impact factor: 1.967
  5 in total
  1 in total

1.  Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience.

Authors:  Dilraj Kaur Kahlon; Veronique Dinand; Satya Prakash Yadav; Anupam Sachdeva
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-03       Impact factor: 0.900
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.